Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | TNKS | O95271 | 3/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4069890 | 0.99 | PARP1 (0.41) | PARP1TNKSPARP2KDM4ESMN1; SMN2 | |
| SCHEMBL1720126 | 0.87 | KMT2A (0.45) | PARP1KDM4ESMN1; SMN2CDK4CCND1 | |
| SCHEMBL1719750 | 0.85 | PARP1 (0.56) | PARP1KDM4EHRH3CDK4CCND1 | |
| SCHEMBL1719898 | 0.85 | KDM4E (0.46) | PARP1KDM4EHRH3KCNH2CDK4 | |
| SCHEMBL1720207 | 0.85 | PARP1 (0.43) | PARP1TNKS | |
| SCHEMBL1719790 | 0.85 | PARP1 (0.43) | PARP1TNKS | |
| SCHEMBL1720211 | 0.85 | PARP1 (0.43) | PARP1TNKS | |
| SCHEMBL4068289 | 0.84 | PARP1 (0.55) | PARP1KDM4EHRH3CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL1719747 | 0.83 | PARP1 (0.54) | PARP1KDM4EHRH3CDK4CCND1 | |
| SCHEMBL1720066 | 0.81 | PARP1 (0.39) | PARP1TNKSPARP2MPOTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | claimed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | PARP1 1/4885TNKS 127/4885PARP2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.